Score breakdown
Strengths & weaknesses
- 32 Kovera vial reports with an LC-MS identity line; median purity 99.83%
- Publishes add-on panels most shops skip: 17 heavy-metal, 7 endotoxin and 4 sterility reports at Kovera
- A 424-row public certificate ledger, searchable by the batch ID on the vial
- Non-GLP vials 28-67% under our index median per mg
- Finnrick's top retatrutide rating on 9 Oct 2026 (93% across 30 tests)
- Open FDA warning letter 735063 (24 Aug 2026); all six named peptides still on sale on 9 Oct 2026
- Three Kovera fails: Epithalon at 72.85% purity, Semax at 68.7% of label, a semaglutide sterility "Growth"
- The shop's ledger shows passing reports for those three lots, not the fails
- Four vials at 127-132% of label still marked PASS by Kovera
- Wyoming LLC at a registered-agent address plus a Sarasota mailbox; we could not confirm the filing
- Trustpilot profile removed; Finnrick rates it 66%, #332 of 457
What we tested
10 SKUS ORDEREDShipping & payment
MEDIAN ACROSS TEST ORDERSAudit notes
FROM THE BENCHWhat we found
- An open FDA warning letter. Letter 735063, dated 24 August 2026, names six of its peptides and its bac water as unapproved new drugs. All six peptides were still on sale on 9 October 2026. We found no published response.
- A deep lab record. 32 Kovera vial reports with identity confirmed, a median purity of 99.83%, and heavy-metal, endotoxin and sterility panels most shops never buy.
- Three failed reports the shop's ledger leaves out. An Epithalon vial at 72.85% purity, a Semax vial at 68.7% of label and a semaglutide sterility screen reading "Growth". For those lot codes the ledger lists only the passing reports.
- An owner we could not confirm. The policies name Pirsek Technologies LLC at a Wyoming registered-agent address; the contact page gives a Sarasota mailbox. Neither state's registry returned the LLC.
- Low non-GLP prices. 28-67% under our index median per mg.
Peptide Partners scores 50/100. If you buy, check every lot code on Kovera's verifier, not on the shop's ledger.
Is Peptide Partners legit?
It is a real shop that ships and publishes lab reports you can check yourself. A Kovera certificate number typed into Kovera's verifier returns the same record the vendor links. We confirmed its reports that way on 9 October 2026, including all three failures below.
If "legit" includes legal standing, the answer is no. FDA has told the operator in writing that six of its products are unapproved drugs. A clean certificate does not change that: as our August letters article explains, none of the 2026 letters relied on lab testing.
What do Peptide Partners' lab reports show?
Our mirror of Kovera Labs holds 61 records for the client "Peptide Partners", dated 25 February to 16 July 2026. 32 are vial potency reports with purity, net content and an LC-MS identity line. The other 29 are add-on panels: 17 heavy metals, 7 endotoxin, 4 sterility screens and 1 bac water analysis. Our May leaderboard counted 26 records; 11 more came from PDFs on the vendor's site after Kovera closed its public listing.
| Measure | Result |
|---|---|
| Purity, 32 vial reports | median 99.83%, range 72.85-99.99% |
| Fill against label | median 108.6%, range 68.7-131.8% |
| Fills under 90% / over 110% / over 125% | 1 / 13 / 4 |
| Identity by LC-MS | confirmed on 32 of 32 |
| Heavy-metal panels | 17 of 17 pass |
| Endotoxin panels | 7; the 6 with a result all pass |
| Sterility screens | 4, one reading "Growth" |
| Janoshik public reports | none in our mirror of 337 |
The three failures
| Report | Product | Lot | Tested | Result |
|---|---|---|---|---|
| KVR-2026-C06E75 | Epithalon 10 mg | ET202604 | 20 Mar 2026 | Purity 72.85%, batch average 72.83% against ">98%", FAIL |
| KVR-2026-1AF8EF | Semax 30 mg | SX202603 | 24 Mar 2026 | Net content 20.62 mg (68.7% of label), batch average 20.79 mg against "30mg ± 10%", FAIL |
| RSTER-KVR-2026-643CB5 | Semaglutide | SM202607 | published 24 May 2026 | Rapid sterility "Growth", FAIL |
The Epithalon vial held the right peptide: LC-MS confirmed Epitalon as the main compound, but about 27% of the HPLC signal came from other material. That is the lowest purity in the Peptide Partners set by 26 points. A 40 mg vial carrying the same lot code, ET202604, measured 99.86% on 13 May 2026.
Read the semaglutide result with care. Kovera's method text calls the rapid screen "preliminary" and says full USP <71> testing "may be required". A second Kovera report on a vial with the same lot label, KVR-2026-D8F3B3 from 10 June 2026, passed both the rapid sterility screen and endotoxin. We cannot tell from outside whether the two samples came from one production run.
What the shop's ledger shows for those lots
The certificate ledger describes itself as "the most recent third-party analyses". On 9 October 2026 it showed:
| Lot | Failing Kovera report | What the ledger lists instead |
|---|---|---|
| ET202604 (Epithalon) | 72.85% purity, 20 March | 99.86% purity, 13 May |
| SX202603 (Semax) | 68.7% of label, 24 March | 99.91% purity, 31 March |
| SM202607 (semaglutide) | sterility "Growth", published 24 May | passing sterility screen, June |
Showing the newest report per lot is a defensible design. It also means a buyer who reads only the ledger never learns that the lot code once failed. Kovera's verifier keeps the failures.
Overfills marked PASS
Four reports run over 125% of label: thymosin alpha-1 (128.4%), BPC-157 (127.3%), PT-141 (131.0%) and ipamorelin (131.8%). From June 2026 Kovera's net-content specification reads "~10mg" instead of "10mg ± 10%", so 13.18 mg in a 10 mg ipamorelin vial reads PASS. The older specification passed overfill too: the thymosin alpha-1 report (KVR-2026-9E35D5) shows 12.84 mg against "10mg ± 10%" and was marked PASS on Kovera's verifier when we checked on 9 October 2026. In the records we read, Kovera failed only fills below the range. Overfill costs a buyer less than underfill, but a 10 mg label on a 13 mg vial is still wrong.
All 32 vial reports
| Compound | Label | Measured | % of label | Purity | Kovera report | Lot | Tested |
|---|---|---|---|---|---|---|---|
| Thymosin alpha-1 | 10 mg | 12.84 mg | 128.4% | 99.95% | 9E35D5 | TA202602 | 2026-02-25 |
| Epithalon | 10 mg | 10.94 mg | 109.4% | 72.85% | C06E75 | ET202604 | 2026-03-20 |
| Semax | 30 mg | 20.62 mg | 68.7% | 99.93% | 1AF8EF | SX202603 | 2026-03-24 |
| GLOW blend | 70 mg | 75.66 mg | 108.1% | 99.79% | 6E0B96 | GW202603 | 2026-03-25 |
| Tirzepatide | 40 mg | 43.44 mg | 108.6% | 99.99% | 59E1F5 | TZ202603 | 2026-03-26 |
| Semax | 20 mg | 19.84 mg | 99.2% | 99.93% | CAAD42 | SX202603 | 2026-03-31 |
| Sermorelin | 10 mg | 11.46 mg | 114.6% | 99.99% | 547DE8 | SER202601 | 2026-04-01 |
| Pinealon | 20 mg | 21.87 mg | 109.4% | 99.99% | E72260 | PN202603 | 2026-04-01 |
| GHK-Cu | 100 mg | 95.85 mg | 95.8% | 99.95% | B787A6 | CU202604 | 2026-04-03 |
| MOTS-c | 10 mg | 11.24 mg | 112.4% | 99.96% | 1E8D20 | MC202603 | 2026-04-04 |
| SS-31 | 10 mg | 11.73 mg | 117.3% | 99.91% | 030E88 | SS202601 | 2026-04-10 |
| Cagrilintide | 10 mg | 9.84 mg | 98.4% | 99.95% | 18A622 | CG202603 | 2026-04-14 |
| AOD-9604 | 10 mg | 9.68 mg | 96.8% | 99.96% | 803483 | AO202605 | 2026-04-20 |
| BPC-157/TB-500 | 20 mg | 22.03 mg | 110.2% | 99.95% | 322ED2 | BB202605 | 2026-04-21 |
| KLOW blend | 80 mg | 83.66 mg | 104.6% | 99.81% | 902ECB | KW202604 | 2026-04-21 |
| Tesamorelin | 10 mg | 11.61 mg | 116.1% | 99.85% | A01ED6 | TES202604 | 2026-04-21 |
| DSIP | 5 mg | 5.31 mg | 106.2% | 99.85% | 02D521 | DS202605 | 2026-05-07 |
| CJC-1295/ipamorelin/tesamorelin | 40 mg | 42.37 mg | 105.9% | 99.79% | DC032B | CIT202604 | 2026-05-07 |
| Epithalon | 40 mg | 43.47 mg | 108.7% | 99.86% | 667A00 | ET202604 | 2026-05-13 |
| BPC-157 | 10 mg | 10.72 mg | 107.2% | 99.89% | 6181C7 | BC202606 | 2026-05-17 |
| CJC-1295 no DAC | 10 mg | 11.59 mg | 115.9% | 99.33% | B2021B | CJ202606 | 2026-06-09 |
| Retatrutide | 24 mg | 25.40 mg | 105.8% | 99.77% | CD3187 | RT202607 | 2026-06-09 |
| Tirzepatide | 40 mg | 41.36 mg | 103.4% | 99.55% | EB005D | TZ202605 | 2026-06-09 |
| BPC-157 | 10 mg | 12.73 mg | 127.3% | 99.75% | 479A0C | BC202607 | 2026-06-10 |
| Ipamorelin | 10 mg | 13.18 mg | 131.8% | 99.71% | AD226C | IP202606 | 2026-06-10 |
| Semaglutide | 10 mg | 11.98 mg | 119.8% | 99.69% | D8F3B3 | SM202607 | 2026-06-10 |
| KPV | 10 mg | 10.69 mg | 106.9% | 99.70% | DD8FF8 | KV202606 | 2026-06-10 |
| Retatrutide | 12 mg | 11.18 mg | 93.2% | 99.36% | A7DC2C | RTT202606 | 2026-06-20 |
| 5-Amino-1MQ | 10 mg | 11.86 mg | 118.6% | 99.81% | AB315B | AM202604 | 2026-06-20 |
| PT-141 | 10 mg | 13.10 mg | 131.0% | 99.74% | 28597D | PT202605 | 2026-06-25 |
| Kisspeptin-10 | 10 mg | 11.31 mg | 113.1% | 99.71% | F8A885 | KSS2607 | 2026-07-02 |
| Retatrutide | 12 mg | 12.50 mg | 104.2% | 99.78% | 6108FD | RTT2613 | 2026-07-16 |
Values are single-vial figures as held in our mirror after the 1-2 August 2026 re-fetch. Kovera revises some certificates in place (what changed), so its verifier may show a batch average that differs slightly.
What to watch out for
The FDA warning letter
FDA's Center for Drug Evaluation and Research reviewed peptide.partners in July 2026. The letter names "GLP-1 S (Semaglutide)", "GLP-2 T (Tirzepatide)", "GLP-3 Reta (Retatrutide)", "SS-31 (Elamipretide)", "Tesa Peptide (Tesamorelin)", "PT-141 (Bremelanotide)" and "Reconstitution Solution (BAC)" as unapproved new drugs under section 505(a) of the Food, Drug, and Cosmetic Act.
FDA quoted the shop's own research summaries. The retatrutide page called it "the weight-loss drug Retatrutide"; the SS-31 page described "a potential treatment to protect the retina". FDA wrote that selling bac water beside injectable peptides "demonstrates that you intend for your 'Reconstitution Solution (BAC)' to be used in combination for injection", and set aside the "for research use only" label because the website "establishes that your products are intended to be drugs for human use."
The shop's public product feed on 9 October 2026:
| Product FDA named | Status on 9 Oct 2026 |
|---|---|
| GLP-1 Semaglutide | in stock, product description empty |
| GLP-2 Tirzepatide | in stock, product description empty |
| GLP-3 Retatrutide 12 mg and 24 mg | in stock, product description empty |
| SS-31 10 mg and 50 mg | in stock |
| Tesamorelin | in stock |
| PT-141 | in stock |
| Reconstitution Solution (BAC) | listed, out of stock |
The text FDA quoted was gone; the products were still listed, and the homepage featured the retatrutide 24 mg pack above every other product. Our code-name decoder and GLP-3 RT explainer cover the naming pattern, and FDA peptide enforcement 2024-2026 has the wider timeline.
Who runs Peptide Partners?
| Source | What it says |
|---|---|
| FDA letter | Peptide Partners LLC, 8350 Bee Ridge #379, Sarasota, Florida; Pirsek Technologies at a second Sarasota address |
| Contact page | the Bee Ridge address, called a "business mailing address" |
| Privacy policy | "operated by Pirsek Technologies LLC", 75 E 3rd St, Ste 7, Sheridan, Wyoming |
| Wyoming registered-agent roster | that Sheridan address belongs to WY Commercial Registered Agent LLC |
| Terms and refund policy | Wyoming law; Pirsek Technologies as seller |
| Domain (RDAP) | peptide.partners registered 18 March 2025, Amazon Registrar |
Finnrick's vendor report (3 July 2026) says Wyoming, Florida and OpenCorporates searches "did not confirm the filing". Peptide Grades lists "Pirsek Technologies LLC, FL". We could not confirm an LLC in either state. The ledger includes a semaglutide report dated 20 August 2025.
What other raters say
| Site | Rating | Commercial link with Peptide Partners | Where it differs from our read |
|---|---|---|---|
| Finnrick | 66%, #332 of 457; retatrutide 93% | None disclosed; sells a paid vendor report | Counts 28 fails in 103 tests; its top retatrutide row matches Peptide Partners' figures |
| Disclosed Labs | A, 90/100, "104 Passed, 0 Failed" | None disclosed | Shows none of the three Kovera fails and no FDA context |
| Peptide Grades | A, 5.0/5 transparency | Not stated | Lists the entity as a Florida LLC |
| PeptideBenchmark | Curated, "near the top" | Yes, disclosed referral link and 10% code | Spotlight dated 30 June 2026, before the FDA letter |
Finnrick's retatrutide table puts a vendor at $4.79 per mg, 93%, 30 tests in first place; those are the figures on Finnrick's Peptide Partners page. The shop's homepage line "Independent analysis ranks Peptide Partners #1 for overall peptide quality" does not name the analysis. Finnrick's overall rank for the shop is 332nd.
Trustpilot shows the profile as removed because the business "goes against our guidelines". On Reddit, most posts naming the shop in the past year are PeptideBenchmark affiliate posts or summaries of the FDA letter. One January 2026 buyer wrote that they "can find no info on how much reconstitution solution to use". We found no lookalike shop using the name; searches also return peptide.com, an unrelated peptide synthesis company.
Payments, shipping and refunds
| Topic | What the shop states (9 October 2026) |
|---|---|
| Payment | The public cart endpoint lists a Tagada card processor, PayPal, Klarna, Afterpay and bank transfer. We did not start a checkout, so we have not seen which ones a given order gets. |
| Delivery time | None stated. The shipping page warns orders "may take extra time due to high demand". |
| Destinations | US only; we found no international option |
| Cancellations | full refund only before shipment |
| Damaged or wrong items | report with photos within 48 hours |
Pricing
Peptide Partners sells in packs, the smallest usually two vials. Against our vendor pricing index (nine vendors, built 25 June 2026), the smallest non-GLP packs on 9 October 2026 came in under the median. We leave the FDA-named GLP products out.
| Product | Smallest pack | $/mg | Index median $/mg | Difference |
|---|---|---|---|---|
| BPC-157 | 2 × 10 mg, $106 | 5.30 | 8.43 | -37% |
| TB-500 | 2 × 10 mg, $130 | 6.50 | 10.22 | -36% |
| MOTS-c | 2 × 10 mg, $79 | 3.95 | 6.10 | -35% |
| GHK-Cu | 2 × 100 mg, $150 (out of stock) | 0.75 | 1.04 | -28% |
| NAD+ | 2 × 900 mg, $198 | 0.11 | 0.33 | -67% |
How we scored Peptide Partners
| Subscore | Weight | Score | Main reason |
|---|---|---|---|
| COA quality | 40% | 6.8 | 32 vial reports with identity; 2 vial fails and 1 sterility fail; ledger omits the fails; overfills up to 131.8% marked PASS |
| Pricing | 25% | 7.8 | Non-GLP vials 28-67% under our index median per mg |
| Shipping | 20% | 6.0 | No stated timeframe, a high-demand delay notice, no order of ours |
| Support | 15% | 4.5 | Mailbox address, registered-agent entity, no refunds once shipped, Trustpilot profile removed |
The weighted subscores come to 6.5. We take 1.5 off for the open FDA warning letter, three times the regulatory-exposure deduction we applied to Hello Stacks, which has no letter. A warning letter is FDA's written finding about named listings, and this one has no public response while the listings stay up. That gives 5.0. The rubric is on our methodology page.
Verdict
Buy from Peptide Partners only if you want a lot code you can trace to a lab report, and you check that code on Kovera's verifier rather than the shop's ledger, because only the verifier keeps the failures. Skip it if legal exposure counts in your decision: FDA named six of its products, we found no published response, and those products still lead its homepage. For a deep Kovera record without a warning letter, Ion Peptide holds the largest clean set in our mirror.
FAQ
Is Peptide Partners legit? It is a real, operating shop with a deep lab paper trail: 32 Kovera vial reports in our mirror at a 99.83% median purity, plus heavy-metal, endotoxin and sterility panels. It also holds an open FDA warning letter (735063, 24 August 2026), and three Kovera reports failed. We score it 50/100 on public data; we have not placed an order.
Did FDA send Peptide Partners a warning letter? Yes. Letter 735063, dated 24 August 2026, says FDA reviewed peptide.partners in July 2026 and found its semaglutide, tirzepatide, retatrutide, SS-31, tesamorelin and PT-141 listings, plus its "Reconstitution Solution (BAC)", to be unapproved new drugs. On 9 October 2026 the shop still listed all six peptides; the text FDA quoted was gone and the bac water was out of stock.
Where is Peptide Partners located and who owns it? The contact page gives 8350 Bee Ridge Rd #379, Sarasota, Florida, a numbered mailbox. The privacy policy and terms name Pirsek Technologies LLC, Wyoming law, and 75 E 3rd St, Sheridan, Wyoming, the address of a commercial registered agent. We could not confirm the LLC filing in Wyoming or Florida.
Which labs test Peptide Partners peptides? Its ledger lists TrustPointe, Kovera Labs, Chromate and BioRegen. Kovera reports can be checked on Kovera's public verifier, which also keeps failed results. Rows dated September and October 2026 name Chromate or TrustPointe; the newest Kovera row is dated 22 August 2026. We have not assessed the other three labs.
Does Peptide Partners still sell retatrutide after the FDA letter? Yes. On 9 October 2026 the shop listed "GLP-3 Retatrutide" in 12 mg and 24 mg vials as in stock, along with "GLP-2 Tirzepatide" and "GLP-1 Semaglutide". All three are named in FDA's August letter. We report this as regulatory exposure, not as a finding about product quality.
Does vialaudit earn commission from Peptide Partners? No. We have no commercial relationship with Peptide Partners. This page carries no affiliate link and no coupon, and the visit link goes to the plain homepage.
What we read, and what we did not
We read the 61 Peptide Partners records in our Kovera mirror and re-checked 42 of them on Kovera's verifier (the three fails, 13 other vial reports and 26 of the 29 add-on panels). We also read our Janoshik mirror, the vendor's 424-row certificate ledger and one ledger PDF, its product feed (42 products) and policy pages, FDA letter 735063, RDAP, the Wyoming registered-agent roster, four rater sites and Reddit search results, all on 9 October 2026.
We did not open checkout, order a vial, or contact Peptide Partners, Kovera or FDA. We read only the public summary of Finnrick's paid report. Wyoming and Florida business searches did not return Pirsek Technologies LLC, so the entity's status is unconfirmed. We did not open every ledger PDF from TrustPointe, Chromate or BioRegen and have not assessed those labs.
Documents we read
All retrieved 9 October 2026 unless noted.
- FDA: warning letter 735063, Peptide Partners LLC, 24 August 2026
- Peptide Partners: home, certificate ledger, product feed, retatrutide 12 mg page, shipping, payment policy, refund policy, terms, privacy policy, contact
- Kovera Labs: verifier; report links in the tables above
- Registries: RDAP for peptide.partners via rdap.org, Wyoming commercial registered agent roster
- Raters: Finnrick vendor page, Finnrick vendor report summary (3 July 2026), Finnrick retatrutide table, Disclosed Labs, Peptide Grades, Trustpilot
- Reddit: PeptideBenchmark spotlight, 30 June 2026, r/BodyHackGuide, 16 January 2026
- Pricing: our vendor pricing index, built 25 June 2026
Sources
6 REFERENCES- FDA warning letter 735063, Peptide Partners LLC, 24 August 2026 — FDA
- Peptide Partners independent certifications ledger — vendor
- Kovera Labs public verifier — third-party-lab
- Finnrick vendor page, Peptide Partners — Finnrick
- Wyoming Secretary of State commercial registered agent roster — Wyoming SOS
- vialaudit - FDA and Lilly peptide letters, August 2026 — vialaudit